Impact of Sirflox failure to meet primary end point, page-29

Your right current treatment is awful so maybe Oncosil would be preferable.

As mentioned by Oncosil for Pancreatic Cancer
Poor prognosis -Median survival ~8 months and 5 year survival less than 7%

World market for pancreatic drugs is projected to exceed $1.2b by 2015

Current Chemo regime in excess of $60,000 per annum

High unmet medical need. • Pancreatic cancer has one year survival of 26%


Oncosil results to date for Pancreatic Cancer

Median overall survival was 309 days or 10+ months (compared with a typical 5.7 months with gemcitabine alone)

Potential Market Size (>105,000 pts p.a)
Total Market Opportunity for Oncosil in Pancreatic Cancer (>$1 Billion)

OSL Cash reserves to Q4 2016, Directors invested substantial amounts higher than current price.